Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study
August 12, 2024 16:10 ET
|
OncoCyte Corporation
Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study
Oncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 Results
August 08, 2024 16:05 ET
|
OncoCyte Corporation
Oncocyte Announces Successful GraftAssureTM Beta Launch and Q2 2024 Results
Oncocyte Announces August Investor Conferences Participation
August 05, 2024 16:05 ET
|
OncoCyte Corporation
Oncocyte Announces August Investor Conferences Participation
Oncocyte to Announce Second Quarter 2024 Financial Results on August 8
August 01, 2024 16:05 ET
|
OncoCyte Corporation
Oncocyte to Announce Second Quarter 2024 Financial Results on August 8
Oncocyte Appoints Andrea James as Chief Financial Officer
June 17, 2024 16:05 ET
|
OncoCyte Corporation
Oncocyte Appoints Seasoned Finance Executive Andrea James as Chief Financial Officer
Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine
May 30, 2024 16:47 ET
|
OncoCyte Corporation
Late-breaking presentation of data at American Transplant Congress on Monday, June 3Data show potential to monitor for therapeutic efficacy and recurrencePotential repeat testing opportunities with...
Oncocyte Reports First Quarter 2024 Financial Results
May 15, 2024 16:05 ET
|
OncoCyte Corporation
ONCOCYTE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
Oncocyte to Announce First Quarter 2024 Financial Results
May 13, 2024 08:00 ET
|
OncoCyte Corporation
Oncocyte to Announce First Quarter 2024 Financial Results
Oncocyte Reports Full Year 2023 Financial Results
April 12, 2024 06:00 ET
|
OncoCyte Corporation
ONCOCYTE REPORTS FULL YEAR 2023 FINANCIAL RESULTS
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
April 11, 2024 21:46 ET
|
OncoCyte Corporation
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules